Navigation Links
Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream
Date:10/11/2011

LONDON, October 11, 2011 /PRNewswire/ --

PAT and QbD remains a field that still lacks clarity and commonality in understanding. In a recent industry-survey released by Pharma IQ across the PAT and QbD community it was  found that 53% of end users said the key reason they were not implementing PAT/QbD was due to a lack of personnel with expertise in the field.

However, Pharma IQ once again opens its doors to industry specialists from the PAT and QbD community and creates an opportunity to learn from leading minds in the industry, increase understanding in companies and cut costs and increase efficiency by learning the best practice approaches to implementing PAT and QbD at  the 9th Annual PAT and QbD conference on the 20 - 22 February, 2012, Thistle Marble Arch, London, UK.

For full event information visit: http://www.patandqbd.com/news

Brett Cooper, Research Fellow, MSD Development Laboratories will be speaking at the conference about PAT and QbD within the early development space. On this he mentions: "This is becoming an increasingly important area of interest within MSD."

Nuno Matos, a PAT Specialist from Hovione is also speaking at this industry event and he adds: "I also look forward to discussing the role of the CMO in the integration of QbD/PAT methodologies across the drug substance and drug product supply chain during development and commercial manufacturing."

Furthermore, the conference agenda includes a number of regulatory orientated talks, opportunities to speak directly with regulators during interactive panel discussions and a fantastic panel of speakers with perspectives offered by 3 regulatory bodies.

Find the full program, event details and registration information on http://www.patandqbd.com/news or email enquire@iqpc.co.uk

Media contact: Veronica Araujo, +44(0)20-7368-9748, veronica.araujo@iqpc.co.uk or visit http://www.patandqbd.com/news

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Veronica Araujo (veronica.araujo@iqpc.co.uk)



'/>"/>
SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development
2. Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market
3. VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance
4. BioMarin Corrects Information Included in Bloomberg Article
5. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
6. The Holtorf Medical Group and Yan Center for Corrective & Cosmetic Surgery Tap 5W Public Relations
7. Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons
8. Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory
9. LASIK and Vision Correction Experts from Trusted LASIK Surgeons Directory Achieve Top Awards at ASCRS Meeting
10. Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S.
11. Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):